P63 and P73 Activation in Cancers with p53 Mutation

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The p53 family (p53, p63, p73) has tumor suppressor roles.
• p53 exhibits high mutation rates in cancers, losing its suppressor function.
• Missense and nonsense mutations are the most common p53 alterations.

Purpose of the Study:

• To review potential drug therapies for p53 missense and nonsense mutations.
• To explore the therapeutic potential of p63 and p73 activators as anti-cancer agents.
• To summarize p63 and p73 activators and strategies to enhance their efficacy, especially for p53 gain-of-function mutants.

Main Methods:

• Literature review of existing research on p53 family mutations.
• Analysis of drug therapies targeting specific p53 mutations (missense, nonsense).
• Summary of p63 and p73 activators and their mechanisms.

Main Results:

• p53 mutations impair tumor suppression, necessitating therapeutic interventions.
• p63 and p73 activators show promise as alternative anti-cancer strategies.
• Strategies for improving activator responses against p53 gain-of-function mutants are discussed.

Conclusions:

• Targeting p53 mutations and utilizing p63/p73 activators represent viable therapeutic avenues in oncology.
• Further research into enhancing p63/p73 activator efficacy is crucial for effective cancer treatment.
• Understanding p53 family dynamics is key to developing novel anti-cancer drugs.